HKSE - Delayed Quote HKD

Brii Biosciences Limited (2137.HK)

1.160 +0.070 (+6.42%)
At close: April 26 at 4:08 PM GMT+8
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 2137.HK

Recent News: 2137.HK

View More
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
PR Newswire last month
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
PR Newswire 2 months ago
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
PR Newswire 3 months ago
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
PR Newswire 5 months ago
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
PR Newswire 7 months ago
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
PR Newswire 8 months ago
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
PR Newswire 9 months ago
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Brii Biosciences Provides Latest Clinical Development and Corporate Updates
PR Newswire 9 months ago
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693

Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
PR Newswire 9 months ago
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
PR Newswire 9 months ago
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
PR Newswire 10 months ago
View More

Related Tickers

1873.HK Viva Biotech Holdings
0.560
0.00%
 
2197.HK Clover Biopharmaceuticals, Ltd.
0.360
+9.09%
 
9939.HK Kintor Pharmaceutical Limited
0.960
+2.13%
 
1877.HK Shanghai Junshi Biosciences Co., Ltd.
10.740
+4.88%
 
6160.HK BeiGene, Ltd.
91.950
+2.17%
 
AVXT AVAX Technologies, Inc.
0.0001
0.00%
 
2179.HK Jiangsu Recbio Technology Co., Ltd.
9.130
0.00%
 
1477.HK Ocumension Therapeutics
6.470
+7.83%
 
41X.F Ardelyx, Inc.
5.83
-3.60%
 
2157.HK Lepu Biopharma Co., Ltd.
5.040
+7.23%